John Paulson’s Sarepta Therapeutics SRPT Stock Holding History

John Paulson’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-78,101	Closed	-$2.31M	–	117
2017 Q1	$2.31M	Buy	+78,101	New	+$2.42M	0.03%	83

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

John Paulson's SRPT Position: Q2 2017 in Review

John Paulson sold out of Sarepta Therapeutics (SRPT) in Q2 2017, closing a stake of 78,101 shares — an estimated $2.31M sold.

John Paulson first reported a position in SRPT in Q1 2017 and held it in 1 quarter. The position peaked at $2.31M in Q1 2017. 190 funds tracked by Wall St. Rank hold SRPT as of Q2 2017.

John Paulson reported no remaining Sarepta Therapeutics position as of Q2 2017 after selling out during the quarter.
John Paulson sold 78,101 Sarepta Therapeutics shares in Q2 2017, an estimated $2.31M.
John Paulson first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 1 quarter.
John Paulson's Sarepta Therapeutics position peaked at $2.31M in Q1 2017.
190 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2017.

Based on Paulson & Co's 13F filing for Q2 2017, filed 14 Aug 2017.